Media coverage about Iqvia (NYSE:IQV) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Iqvia earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 45.6461089719456 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern’s scoring:
Iqvia stock traded down $0.80 during trading hours on Friday, hitting $97.27. The company had a trading volume of 602,628 shares, compared to its average volume of 867,562. The stock has a market cap of $20,425.05, a P/E ratio of 22.31, a P/E/G ratio of 1.67 and a beta of 0.63. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 1.21. Iqvia has a one year low of $81.43 and a one year high of $110.67.
Iqvia (NYSE:IQV) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $1.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.02). The company had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.14 billion. Iqvia had a net margin of 13.44% and a return on equity of 13.03%. The firm’s revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.09 earnings per share. equities analysts anticipate that Iqvia will post 5.02 earnings per share for the current fiscal year.
IQV has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $112.00 target price on the stock in a report on Thursday, January 18th. Evercore ISI initiated coverage on shares of Iqvia in a report on Thursday, January 18th. They issued an “outperform” rating and a $112.00 target price on the stock. SunTrust Banks reaffirmed a “hold” rating and issued a $110.00 target price on shares of Iqvia in a report on Monday, January 22nd. Mizuho set a $97.00 target price on shares of Iqvia and gave the company a “hold” rating in a report on Wednesday, January 24th. Finally, JPMorgan Chase upped their target price on shares of Iqvia from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $110.47.
In other Iqvia news, Director Michael J. Evanisko sold 816 shares of the stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $100.00, for a total transaction of $81,600.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Robert Parks sold 896 shares of the stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $105.73, for a total transaction of $94,734.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,527 shares of company stock worth $1,257,834. Company insiders own 6.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/21/iqvia-iqv-receives-daily-news-impact-score-of-0-19.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.